Core Viewpoint - The article discusses a groundbreaking research study that introduces a long-lasting CAR-T cell platform for the delivery of biologics, specifically targeting chronic diseases like obesity and diabetes, offering a potential single-dose treatment solution [7][8][20]. Group 1: Research Breakthroughs - The research team from Tsinghua University developed a revolutionary long-lived CAR-T cell, named GD2TIF, which can deliver GLP-1 for obesity and diabetes treatment with a single injection, maintaining long-term effects [8][18]. - The study published in *Nature Communications* on August 29, 2025, highlights the potential of GD2TIF cells to provide a "one-time treatment, long-term effectiveness" solution for chronic diseases [9][20]. - Previous methods, such as using AAV vectors for gene delivery, have limitations in providing long-term therapeutic effects due to their transient nature [9][10]. Group 2: Mechanism and Efficacy - GD2TIF cells can secrete GLP-1, achieving sustained weight maintenance and normal blood sugar levels in obesity mouse models, thus meeting clinical "cure" standards [18][20]. - The research emphasizes the importance of selecting GD2 as a target, as it is highly expressed in certain tumors but minimally in normal tissues, reducing the risk of off-target effects [16][17]. - The innovative approach of using CAR-T cells as "living factories" for therapeutic proteins aims to address the challenges of traditional biologic treatments that require frequent injections [10][11]. Group 3: Future Implications - The successful development of GD2TIF cells as a reliable platform for biologic delivery could revolutionize treatment for various chronic diseases, potentially reducing the burden of continuous medication and frequent medical visits for patients [20]. - The article notes that while the cost of CAR-T cell therapy remains high, advancements in cell therapy technology and scalable production could make this long-term delivery method more cost-effective compared to traditional repeated injections [20].

Core Insights - The number of companies in the Shanghai Stock Exchange (SSE) announcing positive earnings forecasts for 2025 is increasing, indicating a recovery in performance and a solid foundation for the "14th Five-Year Plan" period [1][7][9] Group 1: Performance Highlights - As of February 9, 2026, 271 companies on the SSE main board have issued positive earnings forecasts for 2025, with 168 expecting profit increases and 85 companies turning losses into profits [1] - The performance of companies is particularly strong in the non-ferrous metals and electronics sectors, with leading companies maintaining high profit levels [2][8] - In the non-ferrous metals sector, companies are experiencing a "volume-price resonance," with both production increases and rising prices contributing to profit growth [2][8] Group 2: Sector-Specific Insights - Non-ferrous metal companies are benefiting from rising prices and increased production, with Zijin Mining expected to achieve a net profit of 51-52 billion yuan, a year-on-year increase of 59%-62% [2] - The electronics sector is driven by AI demand, with companies like Huaqin Technology forecasting a revenue increase of 54.7%-56.1% and a net profit increase of 36.7%-38.4% [3] - The AIoT market is rapidly growing, with companies like Rockchip expecting significant revenue and profit growth due to increased demand in automotive electronics and AI servers [3] Group 3: Industry Trends - The semiconductor and biopharmaceutical sectors on the STAR Market are showing signs of recovery, with nearly 60% of companies reporting profit growth [5][6] - The integrated circuit industry is benefiting from AI applications, with 87 companies reporting a combined net profit increase of approximately 99.49 billion yuan [5][8] - The biopharmaceutical sector is experiencing a resurgence, with innovative drug companies reporting significant revenue growth and improved profitability [6] Group 4: Future Outlook - The earnings forecasts reflect structural optimization and profitability recovery, indicating a strong foundation for the Chinese economy amid complex challenges [7][9] - The focus on innovation and structural optimization will be crucial for the next five years, with SSE companies playing a key role in driving economic stability [9][10] - The continuous improvement of the capital market environment is expected to attract long-term investment, fostering a positive cycle between technological innovation and capital support [10]

Group 1: Overall Market Performance - Over 270 companies on the Shanghai Stock Exchange have issued positive performance forecasts for 2025, indicating a robust outlook for the market [1] - Nearly 60% of companies on the Sci-Tech Innovation Board have reported year-on-year profit growth, showcasing the dual dimensions of quality and quantity in the economic trajectory of China [1] Group 2: Nonferrous Metals Industry - The nonferrous metals industry is experiencing a boom driven by resource prices and industrial upgrades, with industrial added value growth of 6.9%, surpassing the national average [2] - The total profit for ten major nonferrous metals reached 528.45 billion yuan, a year-on-year increase of 25.6%, marking a historical peak [2] - Leading companies like Zijin Mining are expected to see significant profit increases, with projected net profits of 51 to 52 billion yuan, reflecting a growth of 59% to 62% [2] Group 3: Electronic Industry - The electronic industry is witnessing growth driven by AI demand, with companies like Huaqin Technology expected to achieve revenues of 170 to 171.5 billion yuan, a year-on-year increase of 54.7% to 56.1% [4] - Shengyi Technology anticipates a net profit increase of 87% to 98%, benefiting from rising sales and improved product structure in the copper-clad laminate sector [4] - Companies are leveraging AI advancements to enhance their product offerings, with firms like Rockchip expected to see revenue growth of 71.97% to 85.42% [5] Group 4: Sci-Tech Innovation Board - The Sci-Tech Innovation Board is showing strong innovation momentum, particularly in the integrated circuit and biopharmaceutical sectors, with a projected net profit increase of approximately 99.49 billion yuan across 87 companies [6] - Companies in the AI chip sector are expected to see revenue growth exceeding 100%, with significant improvements in profitability [6] - The biopharmaceutical industry is transitioning towards commercialization, with notable collaborations and product approvals driving growth [6]

Core Viewpoint - The Hong Kong IPO market has become increasingly active in 2026, with insurance capital accelerating its investments in this market, highlighting a trend towards global asset allocation and the pursuit of undervalued quality assets [1][2][6]. Group 1: Insurance Capital Participation - Since January 2026, insurance capital has participated in cornerstone subscriptions for 10 Hong Kong IPOs, with a total subscription amount of HKD 1.558 billion [1][6]. - In 2025, insurance capital participated in cornerstone subscriptions for 12 Hong Kong IPOs, amounting to HKD 2.620 billion [1][6]. - Key cornerstone investors in recent IPOs include Ping An Life and Taikang Life, with significant allocations in companies like Muyuan Foods and Dongpeng Beverage [2][6]. Group 2: Market Dynamics and Investment Preferences - The low interest rate environment has made the Hong Kong market a primary avenue for insurance capital's global asset allocation, with many undervalued quality assets available [2][6]. - Companies listed in both A-shares and H-shares often have H-shares priced at a discount compared to A-shares, making them attractive for insurance capital seeking better valuations and higher dividend yields [2][6]. - Insurance capital is increasingly focusing on "hard technology" and new consumption sectors, with some projects experiencing competitive bidding [3][7]. Group 3: Performance and Tax Advantages - The Hong Kong capital market regained the top position globally for IPO fundraising in 2025, raising USD 37.4 billion, surpassing the total of the previous three years [3][7]. - Newly listed stocks have performed well, with an average first-day increase of 23.8% and a cumulative first-month increase of 30.7%, particularly in the biotech and healthcare sectors [3][7]. - Insurance companies benefit from tax advantages in Hong Kong, as they can avoid corporate income tax on dividends from H-shares held for over 12 months, enhancing their net returns compared to individual investors [8].

Group 1 - Shanghai and Hong Kong are accelerating the deep integration of "technology + finance" to cultivate a new high ground for global innovation resource allocation [1] - Bank of China Shanghai Branch is actively participating in the collaborative development of the Shanghai-Hong Kong International Financial Center, leveraging its global advantages to provide robust financial support for the integration of innovation chains, industrial chains, and capital chains [1] Group 2 - The Bank of China Shanghai Branch has provided comprehensive credit support to a leading domestic lidar company, facilitating its dual listing on the Hong Kong and US stock markets, marking the largest financing scale for a Chinese concept stock IPO in Hong Kong in the past four years [2] - The bank has tailored a comprehensive financial service covering the entire listing process to meet the core needs of hard technology companies in accessing international capital markets [2] Group 3 - In serving an AI chip design company, the Bank of China Shanghai Branch offered customized financial services throughout the company's growth cycle, supporting its successful listing on the Hong Kong stock market [3] - The bank provided integrated services including equity incentive plans and funding coordination to support the company's research and talent stability in both Shanghai and Hong Kong [3] Group 4 - In the biopharmaceutical sector, the Bank of China Shanghai Branch has facilitated cross-border capital flow by participating in the expansion of a large biopharmaceutical merger fund and a Hong Kong biotech fund [4] - The bank aims to establish a new model of cross-border cooperation in biopharmaceuticals, focusing on "Shanghai R&D, Hong Kong financing, and industrial collaboration" to provide efficient capital support for the transformation and industrialization of cutting-edge technologies [4] - Looking ahead, the bank will continue to deepen financial cooperation and innovation linkage between Shanghai and Hong Kong, contributing to the construction of a globally influential technology innovation center [4]

Core Viewpoint - Chengda Biological (688739.SH) has received approval from the National Medical Products Administration for clinical trials of a high-dose influenza virus split vaccine [1] Group 1: Company Developments - Chengda Biological's wholly-owned subsidiary, Chengda Biological (Benxi) Co., Ltd., has been granted a clinical trial approval notice for the high-dose influenza virus split vaccine [1] - The vaccine is developed using the influenza virus strains recommended by the World Health Organization (WHO) and contains four times the effective components compared to the conventional dose [1]

由于尚无产品获批上市，公司至今未产生产品销售收入，于2024年度和2025年前九个月，其他净收入分 别为1122万元和115.8万元(单位为人民币，下同);同期净亏损则分别达到约1.78亿元和1.25亿元。 近日，港交所主板迎来又一家生物医药公司递表——北京普祺医药科技股份有限公司(下称"普祺医药") 正式递交上市申请，中信证券、民银资本为联席保荐人。此前，公司曾在新三板挂牌，并于2025年6月 终止挂牌，按最后交易日股价计算，市值约24亿元。 截至2025年9月，普祺医药现金及现金等价物仅1.55亿元，紧张的资金状况，凸显了公司寻求上市融资 的紧迫性。作为一家尚未有产品商业化的临床阶段药企，普祺医药亟需上市"补血"， 而港交所专为未 盈利生物科技公司设立的18A上市规则为其提供了更为宽松的上市选项，这或许是公司从新三板转向港 股的原因之一。 招股书显示，普祺医药专注于免疫炎症领域，定位"局部递送靶向疗法的领导者"。公司成立于2016年， 以创新设计和局部递送为核心技术平台，深耕特应性皮炎、过敏性鼻炎等慢性炎症疾病。 JAK抑制剂赛道群雄竞逐，普祺医药能否赶上窗口期? 自身免疫疾病已成为全球第三大慢性病，市场 ...

Core Viewpoint - The medical sector is experiencing both "explosive growth" and "cooling" simultaneously, with over 100 medical companies queued for IPOs in Hong Kong, while tightening IPO policies are anticipated [4][5]. Group 1: IPO Trends and Market Dynamics - The performance of new drug IPOs in 2026 is expected to be significantly differentiated, with over 400 companies currently in the queue for IPOs in Hong Kong [8]. - Investors are becoming more mature and demanding higher standards for IPO projects, focusing on companies with successful overseas BD cases and clear product sales expectations [8][9]. - Many companies are considering Pre-IPO financing to hedge against tightening regulations and market risks, with valuations typically in the range of $300 million to $500 million [9][10]. Group 2: BD Transactions and Market Sentiment - The enthusiasm for BD transactions from multinational corporations (MNCs) towards Chinese new drug assets remains high, with China accounting for 50% of global BD transaction volume last year [12]. - However, the perception of Chinese new drugs as "value for money" is diminishing, leading to a potential slowdown in the growth rate of BD transactions [12][13]. - The focus of BD transactions is shifting from oncology to autoimmune and cardiovascular treatments, with a growing interest in complementary pipelines [14][15]. Group 3: AI in Drug Development and Healthcare - AI-driven pharmaceutical companies are gaining traction, with significant funding and BD opportunities expected in 2026, although the market is becoming increasingly competitive [20][21]. - The application of AI in consumer medical devices and digital therapies is anticipated to unlock new opportunities, particularly in home healthcare products [23][24]. - AI's role in enhancing clinical decision-making and patient management is expected to revolutionize healthcare delivery, making medical information more accessible [24][25]. Group 4: Medical Device Market Outlook - The investment landscape for innovative medical devices is currently at a low point but is expected to gradually improve, with structural investment opportunities emerging [33][34]. - The challenges of international expansion for medical devices are greater than for new drugs, but there are signs of improvement as leading Chinese manufacturers enhance their product capabilities [37][38]. - The future of medical device exports is shifting towards local production and direct sales networks, moving away from simple product exports [38][39].

区域协同创新的核心逻辑，在于实现资源禀赋的错位竞争与深度融合。北京拥有无与伦比的原始创新能 力。这里是国家实验室、顶尖高校和科研院所的集聚地，是"从0到1"的策源地；天津拥有深厚的近代工 业底蕴和完备的先进制造体系，是科技成果中试、转化的理想场所；河北则拥有广阔的产业腹地和应用 场景，是承接高新技术产业落地、实现"从1到100"规模化扩张的坚实后盾。 当京津冀各自的禀赋通过协同创新紧密连接，所形成的不仅是一个完整的产业链条，更是一个自我迭 代、共生共荣的创新生态系统。 这种"1+1+1＞3"的力量，源于创新要素流动的低成本与高效率。随着国际科创中心的扩围，三地之间 的制度成本正在持续降低。通过建立跨区域的创新券通用机制、大型科研仪器共享平台以及人才资质互 认体系，研发在北京、孵化在天津、转化在河北的模式已日趋成熟。 这种机制上的"加法"，往往能带来产业能级上的"乘法"，让每一项科研投入都能在更广阔的地理尺度上 产生震荡效应。 ▲机器人正在展示"穿针引线"。图/央视新闻 2月9日至10日，中共中央总书记、国家主席、中央军委主席习近平深入北京科创园区、养老服务街区、 新春市集考察。考察期间，他强调，北京要立足城市 ...

格隆汇2月12日丨瑞普生物(300119.SZ)公布，为推进公司核心战略落地，拓展重点领域业务边界与行业 影响力，充分借助专业机构的资本与资源优势，瑞普生物股份有限公司于2026年2月12日与海通并购 （上海）私募基金管理有限公司（简称"海通并购资本"）、海通开元投资有限公司（简称"海通开元投 资"）、高邮市产业引导基金（有限合伙）（简称"高邮产业引导基金"）及关联方天津瑞晟私募基金管 理有限公司（简称"瑞晟私募"）签署《江苏国泰海通瑞普并购产业基金合伙企业（有限合伙）之合伙协 议》，拟共同出资设立江苏国泰海通瑞普并购产业基金合伙企业（有限合伙）（暂定名，以市场监督管 理机关核准的名称为准，简称"合伙企业"）。该合伙企业将聚焦动物保健、合成生物、宠物、生物医药 等重点领域开展产业投资。合伙企业认缴出资总额为人民币10亿元，其中，公司作为有限合伙人以自有 资金及自筹资金出资人民币2.95亿元，占合伙企业认缴出资总额的29.50%。 ...